Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan vs Everolimus in Advanced Renal Cell Carcinoma
NCT04195750Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of belzutifan in renal cell carcinoma (RCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival at 39 months and Overall Survival at 49 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04195750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195750.